Bonum Therapeutics
Seattle, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $93M
Overview
Engineering targeted protein degraders to eliminate disease-causing proteins in cancer and immune disorders.
OncologyImmunologyProteomics
Technology Platform
A proprietary platform for designing bifunctional targeted protein degraders (PROTACs and molecular glues) that recruit E3 ubiquitin ligases to eliminate specific disease-causing proteins.
Funding History
1Total raised:$93M
Venture$93M
Opportunities
Potential to drug high-value, previously intractable targets across multiple therapeutic areas with a single modular technology.
Risk Factors
Unproven clinical safety and delivery challenges for degraders, alongside intense competition and intellectual property battles.
Competitive Landscape
Enters a fast-moving field dominated by well-capitalized players, requiring innovative chemistry and novel E3 ligase engagements to stand out.